• SHRG announces Elevate MAX(TM), newest featured beverage in Elevacity nootropic product line
• ‘Happy coffee’ targets increasing consumer demands for additional functional beverages with potential health benefits such as weight management, mood enhancement, extreme energy
• New beverage features its D.O.S.E. formulation, designed to increase levels of key hormones associated with happiness

Sharing Services Global Corporation (OTCQB: SHRG) recently unveiled its newest product – Elevate MAX, a new featured beverage in its Elevacity nootropic product line. Launched during SHRG’s Happiness Revolution LIVE virtual event, product sales for the new offering have exceeded expectations and outperformed all prior product launches (http://ibn.fm/oTMh8).

Elevate MAX is more than just a cup of coffee; this ‘happy coffee’ targets increasing consumer demands for additional functional beverages with potential health benefits such as weight management, mood enhancement and extreme energy (http://ibn.fm/qwDVY).

“We completed extensive market research with outstanding results and are pleased to report the sales of Elevate MAX has exceeded our expectations and surpassed any prior product launches,” Keith Halls, president and CEO of Elepreneurs Holdings LLC, the sales and marketing subsidiary that manages and operates the network of distributors selling the Elevacity product line, stated in a news release.

The newest addition to Elevacity’s line of beverages features the company’s D.O.S.E. formulation, designed to increase levels of four key hormones – dopamine, oxytocin, serotonin and endorphins – proven to be associated with happiness. In addition, the exclusive beverage contains the following (http://ibn.fm/bsIOv):

• A strong blend of polyphenol extracts including apple, grape and mango combined with green tea catechin extract, essential to support and regulate immune functions in the body
• P-synephrine, an efficacious ingredient that acts as a nonstimulant thermogenic agent to increase the breakdown of fats and works synergistically with caffeine to improve exercise performance.
• Adaptogen rhodiola rosea root extract, a natural substance known to increase resistance to stress.

Targeted to assist in enhancing mood, suppressing appetite, strengthening the immune system, and reducing levels of stress while increasing levels of energy, Elevate MAX is the most recent addition to a strong Elevacity product line that was initially released in December 2017. The mission of Elevacity, a wholly owned subsidiary of Sharing Services, is to provide SHRG’s independent sales force, called Elepreneurs, with the safest, most efficacious products formulated to elevate the lives of consumers and Elepreneurs alike. The Elevacity line of functional beverages and supplements are all designed around the company’s proprietary D.O.S.E. formulation and include nonaddictive, natural ingredients with no additives or fillers.

Sharing Services Global Corporation is dedicated to maximizing shareholder value through the acquisition and development of innovative companies, products and technologies in the direct-selling industry. The Sharing Services combined platform leverages the capabilities and expertise of various companies that market and sell products direct to the consumer through independent contractors. Two of its primary divisions include Elevacity Holdings and Elepreneurs Holdings LLC, a sales and marketing company based on utilization of independent contractor distributors who sell the Elevacity product line.

For more information, visit the company’s website at www.SHRGInc.com

NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• POAI subsidiary Helomics helps oncologists individualize cancer treatment using patient-derived tumor models to improve outcomes
• Helomics’ tumor genomic and drug response database is one of the largest in the world with over 150,000 tumors across 137 cancer types
• Expected CAGR of 10.3% from 2018-2024 for oncology segment of precision medicine industry

The relationship between a patient and their cancer is personal: it’s specific, and it necessitates personalized treatment to be defeated effectively. Unfortunately, oncologists’ ability to personalize treatment for patients has largely been anything but, often resembling a trial-and-error method. This is largely because we have few targeted treatments or enough actionable data about how tumors with specific mutations respond to drugs. One innovator in the cancer research space, Predictive Oncology Inc. (NASDAQ: POAI), is working to change this dynamic by bringing its cutting-edge, AI-driven predictive models of tumor drug response and outcome to cancer research. These models predict how tumors respond to drugs and can be used for both clinical decision support, i.e. individualizing a patient’s therapy as well as research into new therapies, in partnership with the pharmaceutical and biotech industries.

With a mission to improve the standard of care for cancer patients, Helomics’ TruTumor(TM) platform harnesses the power of the patient’s own living tumor to address challenges oncologists often face when assessing patients and individualizing treatments. The clinically validated (in ovarian cancer) cell-based functional platform is in use today and profiles patient tumors, identifying key biomarkers and how the tumor responds to drugs and helps the oncologist determine a tailored therapy for that patient.

Helomics’ is building AI-driven predictive models by leveraging; a unique database of 150,000 tumor genomic and drug response profiles gathered from over 15 years of clinical testing using its TruTumor platform; access to over 15 years of outcome data from a national network of oncologists; plus a physical biobank of tumor samples that is being sequenced as part of its CancerQuest 2020 initiative (http://ibn.fm/B9mmE) to generate rich genomic profiles.

Along with subsidiaries TumorGenesis and Skyline Medical, POAI brings precision medicine to the treatment of cancer through collaborations with key players in the pharmaceutical, diagnostic and biotech industries. According to Mordor Intelligence Inc, oncology is expected to have the largest share of the precision medicine industry with estimated market dominance in excess of 30% over other precision medicine segments, and a CAGR of 10.3% from 2018 to 2024 (http://ibn.fm/8fqiH).

POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (PDx) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug repose to improve outcomes for the patients of today and tomorrow.

For more information, visit the company’s website at www.Predictive-Oncology.com

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• SRAX conducted two surveys using consumer-driven BIGtoken platform
• Mother’s Day study showed 68% of users purchased gifts, 49% bought online
• COVID-related survey reveals 67% of users afraid of early reopening, 32% intend to immediately purchase non-essential services
• BIGtoken platform encompasses 16 million users across more than 30 countries with $400 million potential projected revenue by January 2022

As a global society adapts to COVID-19 restrictions, consumer patterns and preferences continue to shift – and insights into these changes are more sought-after than ever before. Brands across all industries seek to leverage valuable consumer data to increase sales, and companies like SRAX Inc. (NASDAQ: SRAX), a technology company focused on digital marketing and consumer data management, have valuable resources to meet this need. SRAX recently released two studies showing key insights about changing consumer patterns in connection with the COVID-19 panic. Through the use of its BIGtoken platform, SRAX leverages the consumer data of its 16 million users to create valuable data sets that are accessible by marketers for a fee. The company also compensates its users with cash or gift cards when they opt in and give access to their data.

The first BIGtoken study was conducted with Publicis Groupe, one of the largest marketing and communications companies in the world (http://ibn.fm/dd3jV). Using BIGtoken’s Lightning Insights, millions of consumers were surveyed to analyze their buying activities surrounding Mother’s Day, giving insight into how the current economic conditions are affecting consumption patterns. While the results showed that 70% of the study participants felt Mother’s Day was either ‘neutral’ or ‘not important’, 84% still celebrated the day, 68% bought a gift, and 49% made that purchase online.

In addition to the Mother’s Day survey, the BIGtoken platform was also leveraged to research the sentiments of users regarding the reopening of the United States (http://ibn.fm/I8Nq6), revealing that 67% feared it will lead to an increased spread of the coronavirus while 32% intend to immediately purchase non-essential goods and services once the country reopens. According to the survey, the types of businesses that users intend to visit include state parks and beaches (39.7%), supermarkets and banks (37.2%), barber shops and nail salons (33.3%), restaurants (29.5%), and non-essential retail stores (25.6%).

The unprecedented economic landscape created by COVID-19 and the resulting lockdown has prompted many companies to seek unique insights into consumer behavior so they can adapt to the increasingly challenging business environment. Data gleaned from SRAX’s BIGtoken platform provides valuable consumer insights, allowing brands to draw inferences to inform their marketing strategy.

“BIGtoken is happy to play a role in helping brands understand rapidly changing consumer behaviors during this time,” BIGtoken Executive Vice President George Stella stated in a recent news release. “Because our users are compensated as they share their data, we’re proud to put a little money back in their pockets. We look forward to continuing to use our platform to help in this crisis by connecting brands directly with their customers and providing quick, relevant insights and audiences they can activate.”

With over 16 million users across more than 30 countries, SRAX’s BIGtoken platform compensates users in addition to providing brands the ability to target and access specific niche groups across 25,000 unique market segments with the power to submit specialized queries that include location and purchase history. Potential revenue for BIGtoken is projected at $400 million by January 2022, with plans to formally launch into several international markets that include Europe, India and Mexico.

Along with BIGtoken, SRAX also unlocks data for the finance space through Sequire – its premier platform for investor intelligence and communication that allows public companies to track investor behaviors and trends for use in engaging current and potential investors.

With an aim to deliver the tools to unlock the value of data, SRAX’s technology helps brands gain insights across marketing channels in the consumer goods, investor relations, luxury, and lifestyle verticals.

For more information, visit the company’s website at www.SRAX.com

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• Preparing for a record-breaking active hurricane season in Florida
• Working to stop the destructive cycle of storm waste in landfills and disposal sites
• Starting storm season in solid position with recent acquisition, three long-term contracts already in place

While the majority of companies have their eyes on COVID-19 and what recovery from “stay-at-home” orders look like, National Storm Recovery Inc. (OTC: NSRI) is preparing for what looks to be an active hurricane season in Florida.

April 2020 set heat records across the world. According to the National Oceanic and Atmospheric Administration (NOAA), 2020 is set to be earth’s warmest year on record while the European Union’s Copernicus Climate Change Service predicts it will rank as one of the top two (http://ibn.fm/cmj5I). Florida was no exception setting with high-temp records set across the state. Typically, higher temps forecast an active hurricane season as heat and warm ocean water play vital roles in powering the storms. The NOAA has reported that the strip of ocean where hurricanes begin was a full 1.1 degrees Celsius warmer than average.

How does all of this effect hurricane season? An article in the Miami Herald (http://ibn.fm/tMeUZ) quoted Michael Mann, director of the Earth System Science Center at Pennsylvania State University, who stated, “We have these bathtub-like conditions of extreme warmth combined with a La Nina-like state of the climate system. In our statistical model, it’s the same sort of condition we saw in 2005.” The center is predicting anywhere from 15 to 24 hurricanes, with 20 named storms in 2020. In 2005, the United States experienced five hurricanes that made landfall, one of which was Katrina.

Historically storm-waste disposal has created an environmental burden on landfills and disposal sites around the nation, only adding to the problem of climate change and the conditions that create these destructive storms. National Storm Recovery, headquartered in Florida, has created a synergistic and environmentally beneficial solution to stop the cycle. The company collects tree debris that is then processed for recycling and manufacturing into organic, next-generation mulch products that are sold to retailers, landscapers, installers and garden centers.

NSRI is used to weathering storms, and as the company prepares for the upcoming hurricane season, it does so in a solid position. The company recently acquired Mulch Manufacturing and has three long-term contracts already in place: a three-year agreement with one of the largest waste disposal companies to lease their yard waste facility; a three-year contract with two one-year renewals for emergency debris and tree removal services for the town of Oakland, Florida; and a three-year contract with two one-year renewals for tree trimming and removal services for Orange County [Florida] Public Schools (http://ibn.fm/Ie3Yf).

NSRI has proved to be a formidable force amid the storms the United States is facing. Whether those storms are founded in economics or Mother Nature, NSRI has a firm foundation and is standing ready to make a difference for customers, employees and shareholders.

For more information, visit the company’s website at www.NationalArborCare.com

NOTE TO INVESTORS: The latest news and updates relating to NSRI are available in the company’s newsroom at http://ibn.fm/NSRI

• SHRM announces recent acquisition of California-based Ketamine Wellness Clinic of Orange County Inc.
• CEO calls acquisition major milestone as company accelerates vision of establishing sizable footprint of integrated ketamine clinics
• Center is recognized leader in ketamine infusion therapy, research and complementary treatment protocols

With the announcement of its recent acquisition of the Ketamine Wellness Clinic of Orange County Inc., Champignon Brands Inc. (CSE: SHRM) (OTC: SHRMF) (FWB: 496) is taking steps to expand into the United States (http://ibn.fm/rFEOp). The wellness clinic owns and operates a state-of-the-art ketamine infusion treatment center located within the Mission Hospital’s Laguna Beach campus.

“We are thrilled to begin executing on our North American expansion strategy by acquiring our first U.S.-based, revenue-generating ketamine center, the Wellness Clinic of Orange County,” SHRM CEO Dr. Roger McIntyre stated in a news release. “This acquisition represents a major milestone as we begin to accelerate our vision of establishing significant scale and a sizable footprint of integrated ketamine centric clinics committed to providing innovative care and therapeutic options to improve the quality of life of patients suffering from chronic disease states that have failed conventional treatments.”

A Canada-based company dedicated to applying novel and natural treatment protocols with an emphasis on psychedelic medicine, Champignon outlined the acquisition in a term sheet completed with the wellness clinic, a cutting-edge facility that has become a recognized leader in ketamine infusion therapy and is actively involved in research and complementary treatment protocols. Based on impressive peer-reviewed studies and equally attention-grabbing clinical trials, intravenous ketamine has gained prominence as a promising treatment option for many chronic diseases, including depression, anxiety, post-traumatic stress disorder, fibromyalgia and certain pain disorders.

“This is an exceptional opportunity to both collaborate and scale with Dr. McIntyre and the world-class team at Champignon, with the objective of remaining at the forefront of innovation in this burgeoning field,” added Dr. Michael Bronson of the Ketamine Wellness Clinic of Orange County. “We are excited for our patients, both current and future, as we work to provide them with the therapeutic options that they deserve.”

As outlined in the term sheet, Champignon is set to acquire 100% of the clinic and all subsidiary companies of the wellness clinic in exchange for a combination of payments and common shares spread over an 18-month period. The completion of the agreement is subject to several conditions, including but not limited to the execution of a definitive agreement and completion of satisfactory due diligence.

Champignon seeks opportunities to promote the health and wellness benefits of functional mushrooms, which are used in a wide variety of health-care and pharmaceutical products. The company’s flagship e-commerce store, VitalitySuperTeas.com, takes advantage of the burgeoning craft mushroom industry with a selection of mushroom-infused teas and accessories; SHRM is also expanding its preclinical trial pipeline and branching out into alternative medicine and pharmaceuticals.

For more information, visit the company’s website at www.ChampignonBrands.com

NOTE TO INVESTORS: The latest news and updates relating to SHRM are available in the company’s newsroom at http://ibn.fm/SHRM

• Software applications among key 3D printing growth trends for 2020
• SGLB’s PrintRite3D(R) software provides manufacturers with quality control solutions that can be remotely deployed throughout entire supply chain to any location worldwide
• Software solutions for 3D printing estimated at $1.4 billion, expected to exceed $3.9 billion by 2023

Despite the current global economic slowdown, the outlook for 3D printing remains optimistic, according to a recent article highlighting areas of growth for 2020 (http://ibn.fm/lLBgY). Most notably, trends like new product creation, increased aftermarket supply chains, and the race to create novel software applications that monitor quality control are predicted to take center stage. Sigma Labs Inc. (NASDAQ: SGLB), a leading provider of software solutions for the 3D metal printing industry, is positioned to benefit from growth in application development – a key trend – with its patented PrintRite3D(R) software that provides manufacturers with a consistent standard of quality assurance. Sigma Labs’ technology is capable of being remotely deployed throughout the entire supply chain to any location in the world.

Quality control solutions are vital for the industry to realize profits and achieve scale due to the high costs of rejected output and time spent in post-production inspections. With an estimated addressable market of $1.4 billion that is projected to exceed $3.9 billion by 2023, software development remains a key growth factor for the 3D metal printing industry. Accordingly, the venture capital market has shifted focus from hardware to application development, with over $1 billion raised by startups in 2019 and continued flows expected for 2020.

Despite the prevailing economic conditions, investment interest in 3D printing remains high. From its demonstrated flexibility in production, quickly providing medical supplies onsite to its ability to eliminate lengthy procurement processes or long shipping wait times, the technology offers critical solutions to longstanding industry woes (http://ibn.fm/znKmn).

Despite these benefits, quality control still continues to be a primary impediment to full industrialization due to a set of challenges that include a lack of product uniformity, profits lost due to rejected output, and costs associated with time spent in the post-production inspection phase. The 3D printing process creates objects by applying layers of raw material on top of each other, making in-process quality control measures absolutely critical for detecting anomalies in real time to allow for error correction. With its patented PrintRite3D(R) software, SGLB is an industry leader in the provision of quality control solutions that give operators the critical information required to observe the production process and address errors or anomalies taking place in real time. By enabling remote production from any location in the world, PrintRite3D(R) empowers operators to identify and fix machine inconsistencies during the printing process throughout the supply chain, so production can be optimized and modified in real time to produce higher quality yields, thus increasing profits.

PrintRite3D(R) runs on most major brands of 3D metal printers from different manufacturers, allowing for a standardized quality assurance process that can be deployed across the entire production chain. Created specifically for highly demanding precision-focused industries, PrintRite3D(R) is currently being evaluated by tier-1 manufacturers in the defense, aerospace, oil and gas, transportation and biomedical industries.

Founded by a team of Los Alamos National Labs scientists and engineers, Sigma Labs, Inc. originally developed and commercially licensed advanced metallurgical products prior to entering the additive manufacturing industry. As a leading provider of quality assurance software under the PrintRite3D(R) brand, SGLB’s stated objective is to become the de facto provider of quality assurance software to the 3D metal printing industry.

For more information about Sigma Labs, please visit www.SigmaLabsInc.com

NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://ibn.fm/SGLB

• SHRM appoints top depression researcher as new chief executive officer
• McIntyre established Canada’s first-ever center to provide rapid-onset treatments for individuals with mood disorders
• Champignon also announces appointment of new board member

Champignon Brands Inc. (CSE: SHRM) (OTC: SHRMF) (FWB: 496), a Canada-based company dedicated applying novel and natural treatment protocols with an emphasis on psychedelic medicine, has appointed one of the world’s top researchers on depression as its new chief executive officer (http://ibn.fm/rureS). In his new role, Dr. Roger McIntyre brings impressive experience in the ketamine and psychedelic medicine space, a key focus area for Champignon.

“My overarching aim as chief executive officer is to establish Champignon as the apotheosis of integrated ketamine treatment delivery and the commercialization of our own IP psychedelic-based treatments,” McIntyre stated in a news release. “The clinical infrastructure, complementary asset base and human capital that Champignon has acquired leaves me very confident we will provide life-changing treatments for persons with depression, all the while contemporaneously rewarding our investor base.

“I have been honored as a professor of psychiatry and pharmacology at the University of Toronto, as well as a professor at universities across the United States and Asia and currently head the world’s largest clinical R&D network in depression,” McIntyre continued. “The Canadian Rapid Treatment Centre of Excellence [CRTCE], that I envisaged and successfully implemented, is the world’s first integrated clinical and R&D centre in ketamine and psychedelic-based treatments and is identified as the most influential scientific center for depression research.”

A professor of psychiatry and pharmacology at the University of Toronto and head of the Mood Disorders Psychopharmacology Unit at the University Health Network in Toronto, McIntyre also serves as executive director of the Brain and Cognition Discovery Foundation in Toronto; director and chair of the Scientific Advisory Board of the Depression and Bipolar Support Alliance (DBSA) in Chicago, Illinois.; professor and Nanshan scholar at Guangzhou Medical University; and adjunct professor at the College of Medicine at Korea University. McIntyre is also a clinical professor at the State University of New York (SUNY) Upstate Medical University, Syracuse, New York, and a clinical professor in the Department of Psychiatry and Neurosciences, at the University of California Riverside School of Medicine.

McIntyre has been named one of the World’s Most Influential Scientific Minds each year from 2014 to 2019 by Clarivate Analytics. He is renowned as one of the world’s most recognized psychiatrists in relation to mood disorders, and has garnered extensive experience collaborating with private-sector partners, including those in the pharmaceutical, insurance and health-care industries.

“We are extremely pleased and fortunate to be able to bring Dr. McIntyre aboard as CEO,” added Gareth Birdsall, who has been serving as Champignon CEO and will continue in his service as director of Champignon. “Dr. McIntyre is the world’s leading authority on depression and associated mood disorders, which is further crystalized by his foresight in founding Canada’s first integrated mood disorder treatment and integrated research center in the CRTCE. Dr. McIntyre’s clear ability to execute and his entrepreneurial nature, along with a demonstrated capacity to lead and delegate in dynamic and growing organizations, represent the skill sets that Champignon needs as it moves towards our North American clinic expansion and maturing novel drug discovery initiatives.”

In addition to the appointment of McIntyre, SHRM also announced that it had appointed Pat McCutcheon as a member of its board of directors (http://ibn.fm/SHUNQ). McCutcheon currently serves as CEO of MediPharm, a leading global cannabis company. McCutcheon founded MediPharm with the objective of building the first pure-play cannabis company focused solely on extraction and API manufacturing.

“I am excited to join the Board of Directors of Champignon given its leadership position with the only licensed operating ketamine clinic and integrated research centre of its kind in Canada,” said McCutcheon. “I look forward to working with the board and the company’s management team to advance Champignon’s clinical development and expansion program in the US and Canada. I also look forward to assisting the company with its plan to evaluate other assets and new partnerships that will expand its pipeline in the rapidly emerging ketamine and psilocybin for mental health industry that has demonstrated strong potential in a short period of time.”

Prior to his work at MediPharm, McCutcheon held top management roles with several large pharmaceutical companies, including Jansen Pharmaceuticals (Johnson & Johnson), Sanofi and Astra Zeneca, where he was directly responsible for launching a wide range of medical products.

“We are tremendously pleased to have Pat join the Champignon Board,” said Birdsall. “His extensive experience in commercial development across the pharmaceutical industry combined with direct experience operating and scaling highly profitable businesses further strengthens our board with expertise that will accelerate the expansion of our clinical footprint via the establishment of net new clinical entities, as well as industry partnerships for ketamine, psilocybin and MDMA.”

Champignon seeks opportunities to promote the health and wellness benefits of functional mushrooms, which are used in a wide variety of health-care and pharmaceutical products. The company’s flagship e-commerce store, VitalitySuperTeas.com, takes advantage of the burgeoning craft mushroom industry with a selection of mushroom-infused teas and accessories; SHRM is also expanding its preclinical trial pipeline and branching out into alternative medicine and pharmaceuticals.

For more information, visit the company’s website at www.ChampignonBrands.com

NOTE TO INVESTORS: The latest news and updates relating to SHRM are available in the company’s newsroom at http://ibn.fm/SHRM

• Innovative energy-management system producer announces deal with agricultural technology pioneer Clean Seed to expand technology to new industries, markets
• XRO’s technology improves speed, torque and efficiency of electric motors
• XRO is entering commercialization phase; targeting at least eight commercial deals for 2020.

Exro Technologies Inc. (CSE: XRO) (OTCQB: EXROF), a Canadian-based technology pioneer developing an innovative energy-management system, has recently signed a collaboration and supply agreement with Clean Seed Capital Group Ltd. Under the agreement, Exro’s solution will be integrated into Clean Seed’s high-tech agricultural seeder and planter platforms, putting this innovative agricultural equipment manufacturer at the forefront of sustainable agricultural innovation. The integration of Exro’s groundbreaking technology will improve Clean Seed’s SMART Seeder(TM) performance by reducing the power requirements to operate its innovative tools.

“This is another step in the commercialization of Exro’s technology that will expand the capabilities of the world’s electric motors,” Exro CEO Sue Ozdemir stated in a news release announcing the landmark deal (http://ibn.fm/KMEkD). “Clean Seed is a pioneer in improving the efficacy and sustainability of farming. With this new agreement, we will, together, electrify the industry to maximize its potential, driving better productivity and efficient use of energy.”

XRO has developed, patented and implemented its proprietary technology, which converts energy in novel ways to improve the performance of electric motors and generators. The technology enhances electric motor performance to make electric motors smarter with an advanced control algorithm that controls electric motor coils through individual coil switching. There is an enormous demand for Exro’s technology with a massive total addressable market comprising more than one billion cars (http://ibn.fm/170Ub) and hundreds of millions of elevators, diesel generator sets and industrial motors.

Exro’s emphasis for 2020 is progress in the commercialization of its exclusive technology. The new partnership with Clean Seed Capital Group is a major step in that direction, as its unique solutions open up a new realm of opportunities for the agricultural sector.

An innovative agricultural technology pioneer since 2010, Clean Seed is well positioned to introduce XRO’s revolutionary solutions. With the help of XRO’s unrivaled technology, Clean Seed is set out to electrify the agricultural industry, inspiring it to leverage the benefits of sustainable energy while increasing profitability through the reduction of input costs of the farming process.

“We continuously evaluate synergistic opportunities that would align with and drive Clean Seed’s mission of facilitating progress in agriculture through the design, development and implementation of industry-altering technologies rooted in a sustainable foundation,” added Clean Seed CEO Graeme Lempriere, as he announced the collaboration. “This worldwide exclusive collaboration and supply agreement focused on the AG sector will set new benchmarks in the electrification of agriculture.”

This agreement represents Exro’s fifth commercialization deal, partnering the company’s technology with respected names in the agriculture, automotive, marine, electric-bicycle and recreational markets. With at least eight targeted deals, Exro will continue to move ahead with the commercialization of its revolutionary technology during 2020, attracting a lot of attention from the industry and investors alike as its solutions that provide lucrative benefits in multiple industries – automotive, public transportation, agriculture, wind energy, recreational and last-mile vehicles (http://ibn.fm/pQ3bh).

For more information, visit the company’s website at www.Exro.com

NOTE TO INVESTORS: The latest news and updates relating to EXROF are available in the company’s newsroom at http://ibn.fm/EXROF

• InsuraGuest raises limit on Hospitality Liability Policy to $5 million
• Company plans to increase verticals served as demand for insurtech solutions increases
• Insurtech sector set to grow at CAGR of 43% to 2025

The announcement by InsuraGuest Technologies Inc. (TSX.V: ISGI) that it has raised the aggregate policy limit for the property and casualty section of its Hospitality Liability coverage is good news for hotel owners and vacation rental proprietors as well as their guests. InsuraGuest is carving out a vertical in the burgeoning insurtech space. Its Hospitality Liability insurance is just one way the company is contributing to the rapid rise of the digital insurance technology revolution.

Presently, many commercial general liability policies leave both owners and guests exposed to unexpected mishaps and misadventures. In addition, purchasing insurance may be the last thing on the minds of travelers and vacationers rushed to get everything one for their upcoming trips. However, offered through its wholly owned U.S. hospitality subsidiary, InsuraGuest Inc., InsuraGuest’s Hospitality Liability Policy can plug the gaps in existing coverage. With its umbrella-plus policy, the company is offering protection many traditional carriers won’t.

InsuraGuest’s Hospitality Liability Policy offers hotel owners and vacation-rental operators a way to protect properties which their guests can benefit from, a way that guests should welcome. Many travelers and vacationers overlook insurance through omission rather than deliberate choice, or they assume the property where they are staying will have proper coverage in case something happens to them. In a hurry with dozens of last-minute minutiae to attend too, most travelers aren’t focused on what could go wrong.

Hotels and Vacation Rentals purchase ISGI’s Hospitality Liability Policy, which protects the property and can benefit the guest if a covered incident were to occur. The specialized policy affords coverage for theft of personal property while in the guest’s room, as well as accidental medical expense and accidental death and dismemberment, up to policy aggregate limits of $5 million (http://ibn.fm/7DFJh). The novel insurtech product mitigates the risks that owners or management companies face if an accident or theft were to occur during a guest’s stay.

Presently, InsuraGuest is focused on the B2B hotels and vacation-rentals sectors, where the company’s API integrates with clients’ property-management systems to offer guests this specialized guest protection policy. The InsuraGuest platform is currently capable of integrating with approximately 71 different hotel and vacation rental property-management systems, linking it to millions of rooms at properties worldwide.

In addition, the company plans to develop solutions for other verticals in the B2B insurtech sector. The insurance industry has been around since the 18th century and appears to have retained an approach and methodology perhaps more suited to that time. A handful of startups has demonstrated just how antiquated the industry is by eating into market share and amassing colossal revenues. For instance, 2-1/2 years ago, Lemonade, which provides renters insurance, had annual recurrent revenues of $1 million; now it’s a $3.5 billion company (http://ibn.fm/8Wr5K). Who said insurance was a dull business?

For more information, visit the company’s website at www.InsuraGuest.com

NOTE TO INVESTORS: The latest news and updates relating to ISGI are available in the company’s newsroom at http://ibn.fm/ISGI

• From 2018 to 2019, the number of people who cut cable more than tripled
• Video on demand is seeing, predicting continued growth
• Company offering unique options such as ‘moviesodes’ and audition opportunities to app users

Amid the economic turmoil of today, one sector is consistently showing growth during the worldwide pandemic of COVID-19. Already valued at $56.55 billion in 2019, the video on demand (VoD) industry is predicted to reach $120.91 billion by 2025 (http://ibn.fm/Om9N8). With more people looking to social distance and stay at home, the industry continues to see a boom. These same customers are turning to smart television and apps that give them the freedom and financial flexibility to watch what they want when. This exodus is good news for companies such as The Movie Studio Inc. (OTC: MVES), whose business model includes subscription and advertiser video on demand (SVoD/AVoD) along with over the top (OTT) services.

As early as March 25, 2020, an article in Forbes predicted that COVID-19 would create a 50% to 70% surge of internet use, with streaming jumping up by 12% (http://ibn.fm/5mLSp). With the combination of smart television, apps, and more than 12,000 people cutting their cable cords every day, VoD is strategically positioned to explode, with one source noting that 1.6 million customers opted out of cable services in 2018, and, in 2019, that number more than tripled, passing 4.9 million (http://ibn.fm/Mz0Xy).

MVES is disrupting traditional media-content delivery systems with the intention to create a direct-server access platform of its own content for worldwide distribution. The company acquires, develops, produces and distributes independent motion pictures for worldwide consumption and is strategically aligned with distribution brands such as Amazon Prime, Showtime, MGM and others.

The Movie Studio App is available in the Apple App Store and the Google Play Store. The company releases movies in chapter format, which are called ‘moviesodes’. The Movie Studio App also offers a “audition to submission” feature, allowing users to have a role in an upcoming movie.

Based in South Florida, MVES is in preproduction for two films: Cause & Effect is about the seedy underbelly of Miami’s nightlife, while Pegasus, scheduled to be the company’s signature film, is about a young girl and a horse. MVES is currently the only major independent studio located in South Florida.

In addition to providing its own titles, MVES entered into a licensing agreement in April 2020 with FILMHUB, an online marketplace for film creators and streaming services. This allows for the viewing of FILMHUB’s catalog on The Movie Studio App in addition to MVES independent productions. This agreement also makes MVES titles available to FILMHUB and its associated OTT partners, providing a larger audience and fan base (http://ibn.fm/VOBCD).

Previously known as Destination Television Inc., The Movie Studio is strategically positioned to capitalize on the quickly changing viewing habits of audiences worldwide.

For more information, visit the company’s website at www.TheMovieStudio.com

NOTE TO INVESTORS: The latest news and updates relating to MVES are available in the company’s newsroom at http://ibn.fm/MVES